A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter’s Syndrome (NCT04623541)
GCT3013-03/EPCORE CLL-1
This trial is No longer recruiting
Registration number NCT04623541
Program & service
This trial is being run with the Cancer service, and as part of the Haematology program.
Trial phase
Phase 1
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor Constantine Tam
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR